randed drug portfolio. 0317 results were ahead of expectations, and this should add further to management's credibility. In addition, per IMS data, Xifaxan scripts continue to show improvement throughout the first 2 months of 0417 and into early December. If the stay was lifted and the Xifaxan infringe